Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 67% of modeled bridge. Strengths: Revenue per Bed, Bed Count. Risks: Occupancy Rate, Net-to-Gross Ratio. Risk-adjusted uplift: $1.5M (vs $2.2M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $823K | $823K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $792K | $23K | $815K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $126K | $374K | $501K | $1.6M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $26K | $26K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 64.2% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $206K | $411K | $617K | $823K | $823K | $823K | $823K |
| Denial Rate Reduction | $0 | $204K | $407K | $611K | $815K | $815K | $815K | $815K |
| A/R Days Reduction | $0 | $167K | $334K | $501K | $501K | $501K | $501K | $501K |
| Clean Claim Rate | $0 | $13K | $26K | $26K | $26K | $26K | $26K | $26K |
| Cumulative | $0 | $589K | $1.2M | $1.8M | $2.2M | $2.2M | $2.2M | $2.2M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $2.2M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 80% / 18.9x | 84% / 21.3x | 88% / 23.8x | 90% / 25.0x | 92% / 26.2x |
| 9.0x | 75% / 16.4x | 79% / 18.6x | 83% / 20.8x | 85% / 21.9x | 87% / 22.9x |
| 10.0x | 71% / 14.4x | 75% / 16.4x | 79% / 18.4x | 81% / 19.4x | 83% / 20.3x |
| 11.0x | 67% / 12.8x | 71% / 14.6x | 75% / 16.4x | 77% / 17.3x | 79% / 18.2x |
| 12.0x | 63% / 11.5x | 67% / 13.1x | 71% / 14.8x | 73% / 15.6x | 75% / 16.4x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 55% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 3.0x, adding 5.5 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $1.2M | — | $1.2M | 2.8% |
| Year 1 | $1.2M | +$1.4M | $2.6M | 6.4% |
| Year 2 | $1.2M | +$2.2M | $3.4M | 8.3% |
| Year 3 | $1.3M | +$2.2M | $3.4M | 8.3% |
| Year 4 | $1.3M | +$2.2M | $3.5M | 8.4% |
| Year 5 | $1.3M | +$2.2M | $3.5M | 8.5% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $411K | $617K | $823K | $988K |
| Denial Rate Reductio | $407K | $611K | $815K | $978K |
| A/R Days Reduction | $250K | $376K | $501K | $601K |
| Clean Claim Rate | $13K | $20K | $26K | $32K |
| Total | $1.1M | $1.6M | $2.2M | $2.6M |
Peer Context — Where This Hospital Sits
Key metrics vs 86 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 2.8% | -12.9% | -2.9% | 3.1% | P73 |
| Net-to-Gross | 61.7% | 52.5% | 59.7% | 64.2% | P65 |
| Occupancy | 40.9% | 15.5% | 30.7% | 41.6% | P72 |
| Rev/Bed | $2.9M | $1.1M | $1.8M | $2.7M | P80 |
| Exp/Bed | $2.9M | $988K | $1.7M | $2.7M | P78 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.